부산대학교 도서관

The association between the use of sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors and the occurrence of drug‐induced kidney injury has not been evaluated. This study assessed whether the use of SGLT‐2 inhibitors decreases the risk of drug‐induced acute kidney injury (AKI) using the US Food and Drug Administration's Adverse Event Reporting System and the Medical Data Vision database. The occurrence of AKI in SGLT‐2 inhibitor users and dipeptidyl peptidase‐4 (DPP‐4) inhibitor users was compared using both databases. In the US Food and Drug Administration's Adverse Event Reporting System analysis, disproportionality for AKI was observed between DPP‐4 inhibitor users and SGLT‐2 inhibitor users administered nonsteroidal anti‐inflammatory drugs (reporting odds ratio, 0.65; 95%CI, 0.48‐0.88; P <.01) and thiazide diuretics (reporting odds ratio, 0.78; 95%CI, 0.67‐0.90; P <.01). In Medical Data Vision analysis, SGLT‐2 inhibitor users administered nonsteroidal anti‐inflammatory drugs (odds ratio [OR], 0.46; 95%CI, 0.41‐0.53; P <.01), anti–herpes simplex virus drugs (OR, 0.20; 95%CI, 0.07‐0.53; P <.01), thiazide diuretics (OR, 0.50; 95%CI, 0.36–0.71, P <.01), and loop diuretics (OR, 0.71; 95%CI, 0.62‐0.83; P <.01) had a lower incidence of AKI compared with DPP‐4 inhibitor users receiving the same drugs. No differences were observed in the risk of AKI between SGLT‐2 and DPP‐4 inhibitor users administered vancomycin and cisplatin in both databases. The use of SGLT‐2 inhibitors might reduce the risk of drug‐induced AKI caused by some drugs. [ABSTRACT FROM AUTHOR]